Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor perifosine, when combined with temsirolimus, was well tolerated while treating recurrent or progressive malignant glioma during Phase 1 clinical trials.
Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor...
From other sites
at CNBC.com (Nov 6, 2014)
at CNBC.com (Jan 9, 2013)
at CNBC.com (Mar 6, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs